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Abstract
Background: NHS community pharmacies provide effective smoking cessation services; however, there is scope for
increasing throughput and improving quit rates. This trial examines whether the Smoking Treatment Optimisation in
Pharmacies (STOP) intervention can improve smoker engagement to increase service throughput, retention and quitting.
Methods: This study is a pragmatic, cluster randomised controlled trial in 60 pharmacies in England and Wales. All
workers in intervention pharmacies are offered STOP training while control pharmacies provide usual care. The STOP
intervention, based on behavioural and organisational theories, comprises educational sessions for staff and
environmental prompts in the pharmacy. Intervention fidelity is assessed by actors visiting pharmacies posing as smokers.
The primary outcome is throughput, defined as the number of smokers who join the programme, set a firm quit date
and undergo at least one stop smoking treatment session, and is measured using routinely collected data. Secondary
outcomes include retention and quit rates at 4 weeks and continuous abstinence at 6 months verified by salivary
cotinine. Cost-effectiveness is estimated using quality-adjusted life years and the probability that the intervention is
effective at different levels of willingness to pay is calculated.
Discussion: The trial will generate evidence to inform the public health smoking cessation strategy in England and Wales,
and may help to shape service commissioning decisions. The STOP intervention model may help inform the undertaking
of a range of health behaviour change tasks in community pharmacies.
Trial registration: ClinicalTrials.gov, ISRCTN16351033. Retrospectively registered on 21 March 2017.
Keywords: Smoking cessation, Community pharmacy, Recruitment, Retention, Behaviour change, Cluster randomised
controlled trial, Quit rate
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Background
The tobacco epidemic is one of the biggest public health
threats the world has ever faced, killing more than 7 mil-
lion people each year [1]. Although the smoking preva-
lence has decreased recently in the United Kingdom, 19%
of adults still smoke [2], which is a similar proportion to
that observed in other developed countries [2]. A total of
1.7 million UK hospital admissions were recorded for con-
ditions attributed to smoking in 2014/15 (22% more hos-
pital admissions than in 2004/05). Thus, tobacco use has
considerable negative implications for the individual, soci-
ety and the National Health Service [2].
UK national guidance [3] stipulates that all health pro-
fessionals should ask people if they smoke and give brief
advice on smoking cessation, offering referral to the NHS
Stop Smoking Service if appropriate. The Stop Smoking
Service provides evidence-based treatment comprising in-
tensive behavioural support (one-to-one or group), and
discussion of medication options by personnel trained ac-
cording to the National Centre for Smoking Cessation and
Training (NCSCT) standard [4, 5].
A recent systematic review [6] suggested that commu-
nity pharmacy-delivered interventions for smoking ces-
sation (n = 14 studies) can be effective and cost-effective.
However, the number of people using NHS Stop Smok-
ing Services in community pharmacies has declined in
recent years [6, 7] and there is evidence to suggest that
participating pharmacies may target only smokers per-
ceived as likely to quit [4, 7]. Retention of smokers
within the service is poor, with about one-third of those
setting a quit date being lost to follow up [4, 8].
There are no trials specifically focused on approaches to
improve uptake and retention in the NHS community
pharmacy smoking cessation service. Increasing through-
put in this service may increase the numbers of people
successfully giving up smoking, thus helping to reduce the
burden of morbidity and mortality from tobacco use.
The protocol for this study has been written following
the SPIRIT guidance [9] (see Additional file 1 for the
populated SPIRIT checklist).
Study aims
The primary aim of the Smoking Treatment Optimisation
in Pharmacies (STOP) trial is to assess the effectiveness of
a new training and service optimisation intervention (re-
ferred to as the STOP intervention) [10] on smoker
throughput, retention and quit rates in the community
pharmacy NHS Stop Smoking Programme.
The secondary aims are to assess cost-effectiveness
and willingness to pay, smoker cessation, service user
satisfaction with the stop smoking programme and phar-
macy staff self-efficacy in delivery of stop smoking ad-
vice, and to conduct a process evaluation to evaluate
fidelity of implementation, clarify causal mechanisms
and identify factors associated with variation in out-
comes [11].
Intervention and comparator
Intervention group
The intervention community pharmacies are offered the
STOP intervention, a service optimisation and behav-
ioural skills training programme which is theory-driven
and developed following the MRC recommendations for
complex interventions [11] using a behaviour change
framework [12] and embedded theory (social cognitive,
self-determination) [13, 14]. We used a realist review of
smoking cessation interventions in pharmacies [15] and
diffusion of innovations theory [16] to plan optimal
implementation.
Detailed descriptions of the development of the STOP
intervention, including strategies to achieve the intended
aims [4, 8, 10], acceptability and feasibility [17], and
methods for assessing intervention fidelity are published
elsewhere [18].
Control group
Community pharmacies in the control group continue
with their usual practice; that is, delivery of the NHS
Stop Smoking Programme according to the NCSCT
programme [19, 20].
Aims of the STOP intervention
The STOP intervention is targeted at all community
pharmacy staff (including counter assistants as well as
pharmacists) and aims to:
(i) increase throughput of smokers into the Stop
Smoking Programme by building up
communication skills and cessation knowledge of
frontline community pharmacy staff (e.g. counter
assistants); and
(ii) increase retention in the Programme and improve
quit rates by building up consultation skills and
knowledge about smoking cessation in stop
smoking advisors.
Methods
Trial design
A pragmatic, cluster randomised controlled trial was
performed with community pharmacies as the unit of
randomisation. Pharmacies are allocated to the STOP
training intervention or usual care (control group) using
stratified randomisation with a 1:1 ratio.
The flowchart of the STOP trial is illustrated in Fig. 1.
Figure 2 shows a PRagmatic Explanatory Continuum
Indicator Summary (PRECIS)-2 diagram [21] of the
STOP trial at the smoker participant level. Each axis
represents one of nine domains measuring how closely
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the trial is related to real life, scored from 1 = very explana-
tory to 5 = very pragmatic. Pragmatic trials are undertaken
in the real world under usual care conditions and the re-
sults are intended to support a decision to deliver the inter-
vention in routine practice [22]. The STOP trial is at the
pragmatic end of the pragmatic–explanatory continuum.
Setting
Sixty community pharmacies in London and Coventry,
England and Cwn Taf, south east Wales.
Sample size
The expected mean recruitment in a control cluster over
the 11months of the study is 165 (based on pilot/feasibil-
ity data) [17]. We consider that an increase of 33% in the
intervention clusters to 220 would be sufficient to change
commissioning policy. The standard deviation of through-
put is expected to be approximately 63 in both groups,
based on historical data from a service commissioner in
the pilot/feasibility study and local authority data [23]. To
have 90% power to detect this difference at the 5% signifi-
cance level we need 56 clusters. We have added two clus-
ters to each arm to allow for drop out, increasing the
number of community pharmacies required to 60.
In order to assess quit rates, written individual consent
is sought by advisors trained in the research processes
(see Recruitment of smoker service users). Service users
who join the Stop Smoking Programme over the con-
tinuous 11-month period are offered the opportunity to
participate, with the aim of recruiting approximately 20
service users per pharmacy.
Recruitment and randomisation of community
pharmacies
Recruitment of community pharmacies and pharmacy
workers
Eligible community pharmacies are those providing the
NHS Stop Smoking Programme and are identified from
Fig. 1 Flow diagram of progress of clusters and individuals through phases of the trial. STOP Smoking Treatment Optimisation in Pharmacies
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lists provided by service commissioners. Figure 3 gives
an overview of the complex organisational structure of
community pharmacies in England. The pharmacy
owner is approached with an invitation letter or email,
with an enclosed participant information sheet, and then
followed up with a phone call after a few days. A meet-
ing is then scheduled with the lead pharmacist and their
staff (both stop smoking advisors and support or counter
assistants) to discuss the study in detail and obtain writ-
ten informed consent for participation. Following receipt
of written consent, pharmacy characteristics (e.g.
whether the pharmacy is a chain or independent) and
pharmacy staff demographics are collected.
Randomisation
The community pharmacies are randomised to the
STOP training intervention or to usual practice (no
training) in a 1:1 ratio with stratified block randomisa-
tion for the pharmacy commissioner and number of pre-
scriptions dispensed per month per pharmacy (as a
proxy for pharmacy footfall), using an online system to
ensure allocation concealment.
To reduce contamination due to staff crossover in
small-chain pharmacies, a pharmacy chain where the
owner has fewer than five pharmacies is randomised as
one unit. For large pharmacy chains (owner has more
than five pharmacies, e.g. Boots, Superdrug), individual
outlets are randomised; each outlet is a separate rando-
mising unit. The owners of large pharmacy chains or the
head office confirmed to the study team at recruitment
that there would be no staff crossover to the study team,
and this was confirmed during trial monitoring visits.
The study team recruiting pharmacies emails an inde-
pendent statistician with details of consented pharmacies
for allocation. The independent statistician then per-
forms the randomisation and notifies the study team of
pharmacy allocation by email.
Blinding
The smoker service users are blind to the pharmacy’s al-
location. Pharmacy staff are not blind to the intervention
allocation; however, the collection of primary outcome
data is via routine data collection, so the chances of bias
are minimised. Follow-up assessments are conducted by
a team not blind to the experimental intervention; how-
ever, validation of the reported smoking status is by sal-
ivary cotinine test performed by ABS Laboratories,
which is blind to allocation.
Participants
In this study there are two types of participants in rela-
tion to study outcomes and data collection (Table 2):
(1) Pharmacy staff, including stop smoking advisors
and support staff (related to process outcomes).
(2) Service users in participating pharmacies (following
‘gatekeeper agreement’ [25]). The service users
eligible for inclusion are self-reported current
Fig. 2 PRECIS-2 diagram illustrating that the trial lies towards the pragmatic end of the pragmatic–explanatory continuum. The Smoking
Treatment Optimisation in Pharmacies trial was scored for each of nine domains from 1 = very explanatory to 5 = very pragmatic in group
discussion with trialists and methodologists, and the results are displayed as a radar diagram [21]. PRECIS PRagmatic Explanatory Continuum
Indicator Summary
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smokers aged 18 years and older who join the Stop
Smoking Programme and attend the first stop
smoking session (related to the primary outcome).
(2a)A subgroup of service users who give individual,
written, informed consent for additional data
collection procedures (related to secondary
outcomes).
Recruitment of smoker service users
All service users who join the NHS Stop Smoking Ser-
vice in participating pharmacies are considered part of
the trial. Recruitment of service users, consenting for
additional data collection, takes place over an 11-month
period beginning immediately following the staff training
session in intervention pharmacies and 1 month after
the site initiation visit in control pharmacies (Table 2).
Stop smoking advisors in all participating pharmacies
undergo research-related training to take written in-
formed consent and collect saliva samples from consent-
ing service users. All service users who attend the first
stop smoking session of the NHS Stop Smoking
Programme (routine visit 1) are approached by their
stop smoking advisor at the end of the session to partici-
pate in additional data collection procedures (Table 2)
using a study information sheet and consent form. Writ-
ten consent is taken from those interested within 24 h or
at the next appointment in the pharmacy. This time
period was found to be a convenient and acceptable way
to consent service users in the feasibility study [17] and
was approved by the ethics committee. Figure 4 illus-
trates the process of recruitment.
Retention strategies
To maximise retention of pharmacies, pharmacy staff and
service commissioners, we applied evidence-based strat-
egies [26] and findings from our feasibility study [17].
A service contracting agreement is made with each
participating pharmacy that includes the list/protocol of
research-related work to be carried out. Training is pro-
vided in research-specific procedures and monitoring
visits are planned to ensure the advisors carry out the
research activities listed in the service contract. Good
communication and relationships are maintained
throughout between pharmacy staff and the study re-
search team by regular contact using WhatsApp closed
Fig. 3 Illustration of the organisational structure of community pharmacies in England [24]. Proprietor (owner): if owns five or less community
pharmacies, pharmacy is referred to as independent; if owns more than five community pharmacies, pharmacy is referred to as chain
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groups, email and phone calls. WhatsApp messages giv-
ing study information are sent to separately created con-
trol and intervention groups.
Pharmacy staff receive a £10 voucher for returning sal-
iva samples to the study team and service users receive a
£5 voucher for returning the satisfaction questionnaires.
Service commissioners receive reimbursement for the
time taken to send routine smoking cessation data to the
study team at £40/h. STOP intervention training is
incentivised by providing £40 in cash for counter assis-
tants to attend one training session and £80 for pharma-
cists/stop smoking advisors to cover payment for
attending two training sessions, including and travel ex-
penses. Payments are based on hourly rates following
discussion with the local Clinical Research Network
(NOCLOR Research Support Service) that supports re-
searchers in the set-up and conduct of research in pri-
mary care/community clinical settings. A ‘certificate of
completion’ is given to each staff member for attending
and completing the training.
Data collection and measurements
Baseline characteristics
The pharmacy information and staff demographics are
presented in Table 1, and service user demographics are
presented in Table 2.
Primary outcome
The primary outcome measure is throughput assessed
using routinely collected data supplied by service com-
missioners and defined as the number of smokers who:
1. join the stop smoking programme;
2. set a firm quit date; and
Fig. 4 Process of recruitment. NHS SSP, National Health Service Stop Smoking Programme, STOP Smoking Treatment Optimisation in Pharmacies
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3. undergo at least one consultation on or prior to the
quit date (i.e. a ‘treated smoker’ according to the
Russell standard [28]).
Secondary outcomes
Using the Russell Standard criteria [28], we assess the
following:
 The 4-week retention rate—the proportion of
treated smokers retained at 4 weeks. A treated
smoker is counted as ‘lost to follow up at 4-weeks’
(LFU4W) if, on attempting to determine the 4-week
quit status, she/he cannot be contacted. The na-
tional guidance [29] recommends that pharmacy
staff determine the quit status at 4 weeks in at least
85% of cases but there is no guidance given on the
number of attempts allowed to follow up service
users. Hence, the number of attempts and process of
follow up used by staff may vary between pharma-
cies [17].
 The 4-week quit rate—the proportion of smokers
who quit smoking at 4 weeks from the set quit date
(i.e. a ‘carbon monoxide (CO)-verified 4-week
quitter’).
In addition, continuous abstinence assessment of indi-
vidually consented smokers—defined as the proportion
of smokers who quit at 4 weeks (CO-verified) and
remained so at 6 months (ascertained by telephone inter-
view and verified by salivary cotinine)—is determined to-
gether with factors that may influence quit rates (e.g.
gender, ethnicity).
Table 2 describes the type of data collected (i.e. trial
outcome data, process data including intervention fidel-
ity and tissue data), the source of data and the time
point of collection.
The SPIRIT figure (Fig. 5) provides information on the
study visits and the activities/assessments at each visit.
Economic evaluation
A cost-effectiveness analysis comparing the STOP inter-
vention to usual care is conducted from the perspective
of the NHS and personal social services. The cost of
delivering the intervention to participants (e.g. training of
pharmacy advisors and additional time spent consulting
service users) is obtained by the study team and valued
using published sources of UK costs [29, 30].
The intervention cost is combined with lifetime cost
and quality-adjusted life years (QALYs) gained, estimated
using a previously published economic model for analysis
of smoking cessation and relapse [31]. A Markov cohort
simulation predicts the likely smoking status and, subse-
quently, the health status of a cohort of 1000 hypothetical
patients, each receiving a specific treatment strategy. The
model accounts for various smoking-related morbidities,
each associated with a cost and an impact upon the pa-
tient’s quality of life. Mortality rates are also included, for
smokers and former smokers, and survival, combined with
quality of life inputs, is used to generate expected QALYs.
The cost-effectiveness model uses the 6-month quit
rate from the trial as the measure of short-term efficacy
of the intervention. The long-term quit rate is unknown
and is likely to be an important source of uncertainty,
but is calculated using a combination of the 6-month
quit rate, medium-term relapse rates and long-term ‘nat-
ural background’ quit rates, the latter two derived from
the published literature. Background quit rates and the
probability of relapse obtained from the literature simu-
late the proportion of the cohort who remain abstinent
in future years.
One-way sensitivity analyses test the robustness of the
model to assumptions of long-term effectiveness. A
probabilistic sensitivity analysis gauges the combined ef-
fect of uncertainty around all model parameters simul-
taneously. The probability of cost-effectiveness of the
intervention assuming different levels of willingness to
pay per QALY is illustrated using a cost-effectiveness ac-
ceptability plane.
Data management and analysis
Data are stored in the Queen Mary University of London
(trial sponsor) secure virtualised environment with
dual-factor authentication. A full statistical analysis plan
is developed prior to release of allocation codes to any-
one involved in writing that plan. We compare the num-
bers of participants enrolled in the Stop Smoking
Table 1 Baseline demographics
Baseline demographics
Pharmacy information Contractor code, type of pharmacy (independent/chain), total number of staff
(both full-time and part-time), number of stop smoking advisors, number of
pharmacy support staff. The study team also obtain the number of prescriptions
dispensed monthly for each participating pharmacy from the Pharmacy and
Appliance Contractor Dispensing data report
(publicly available) [23]
At baseline Directly from consented
pharmacist/advisor
Pharmacy staff Job title, highest education level, age, gender, smoking status At baseline Directly from consented
pharmacist, advisor and
support staff
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Fig. 5 Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) figure. CO carbon monoxide, GCP Good Clinical Practice,
NCSCT National Centre for Smoking Cessation and Training, NHS SSP, National Health Service Stop Smoking Programme, STOP Smoking
Treatment Optimisation in Pharmacies
Sohanpal et al. Trials          (2019) 20:337 Page 10 of 12
Programme between pharmacies allocated to the STOP
training intervention and those who are not, using a
mixed-effects Poisson regression model with the phar-
macy as the random effect to allow for clustering. The
dependent variable will be the number of ‘treated
smokers’ from each pharmacy. The model will include
two stratification factors—the commissioning site and
the number of prescriptions/forms per month. Other co-
variates to be included in the model will be agreed a
priori before the analysis plan is signed off.
Discussion
This is the first randomised controlled trial to assess the
effectiveness and cost-effectiveness of an intervention
designed to optimise smoker throughput and retention
in the NHS Stop Smoking Programme. The systematic,
theory-based development and iterative refinement of
the intervention before evaluation in the main trial is a
strength of the study [10, 18].
As this is a multi-site trial in different parts of the
United Kingdom, and is taking place in the setting where
patients already receive their usual care, the likelihood
that the findings can be generalised is increased. The
intervention has potential to be modified to support other
public health interventions with health behaviour or clin-
ical outcomes delivered in community pharmacies.
The study is translational in nature with direct impli-
cations for health service provision in NHS community
pharmacies and provides essential data to assess the
cost-effectiveness of the intervention, thus informing
commissioning decisions [32].
Trial status
The trial is ongoing as protocol version 4, dated 21
March 2017. The recruitment period for pharmacies was
from 1 June 2017 to 1 March 2018 and for smoker par-
ticipants was from 1 June 2017 to 1 January 2019.
Additional file
Additional file 1: SPIRIT 2013 checklist: recommended items to address
in a clinical trial protocol and related documents (DOC 122 kb)
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